104 results
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
casting a vote.
After considering the benefits and consequences of each alternative, our board of directors recommends that the advisory vote … and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms
424B7
IMCR
Immunocore Holdings plc
5 Apr 24
Prospectus with selling stockholder info
4:34pm
, but are not limited to, statements about:
the therapeutic potential and expected clinical benefits of KIMMTRAK;
the safety, efficacy and clinical progress of our … , but are not limited to, statements about:
the therapeutic potential and expected clinical benefits of KIMMTRAK;
the safety, efficacy and clinical
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
may abstain from casting a vote.
After considering the benefits and consequences of each alternative, our board of directors recommends … and indirect, of the related persons, the benefits to us of the transaction and whether the transaction is on terms that are comparable to the terms available
S-3ASR
IMCR
Immunocore Holdings plc
20 Mar 24
Automatic shelf registration
8:51pm
, but are not limited to, statements about:
the therapeutic potential and expected clinical benefits of KIMMTRAK;
the safety, efficacy and clinical … of employees of our company or any of our subsidiary undertakings which only gives him benefits which are also generally given to employees to whom
8-K
EX-99.1
IMCR
Immunocore Holdings plc
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
to more patients in the United States, Europe and globally; the potential benefits and advantages KIMMTRAK will provide for patients, including its … collaboration partners or the combined clinical trials with the Company’s collaboration partners; statements regarding the benefits of the Company’s
8-K
EX-99.2
7312nbb
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
10-K
EX-10.12
cktpl9rgms2sc837p7
28 Feb 24
Annual report
7:33am
10-K
EX-10.13
cp45 rhk5
28 Feb 24
Annual report
7:33am
10-K
EX-97.1
xx1ar
28 Feb 24
Annual report
7:33am
10-K
EX-10.14
liw0juj0p35bo1rkryd
28 Feb 24
Annual report
7:33am
10-K
h57vc
28 Feb 24
Annual report
7:33am
8-K
EX-4.1
ftn 8wg104jn
2 Feb 24
Immunocore Prices Upsized Convertible Senior Notes Offering
4:05pm
8-K
EX-99.2
x8vz4s7rn
29 Jan 24
Immunocore Announces Proposed Convertible Senior Notes Offering
5:06pm
8-K
EX-99.1
51zo0496r54i24mpikjy
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
8-K
EX-99.2
8l5lgc5py31pl
5 Jan 24
Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
7:19am
6-K
EX-99.3
vvjqm989e
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.2
03ykn12
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.4
uql5h 62a
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.3
bvpznz4tjmaa
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
rh7i1mxtyp
10 Aug 23
Current report (foreign)
8:28am